Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-05

FDA Approved: BARHEMSYS — Supplemental Application (Acacia Pharma Ltd)

View source ↗

Summary

The FDA is processing a supplemental application for BARHEMSYS (amisulpride) from Acacia Pharma Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Barhemsys (rolapitant)

Snippet

SUPPL AP for BARHEMSYS (AMISULPRIDE)